Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (6553)	3/19/1999 8:43:00 AM
From: LLCF	Read Replies (1) \| Respond to of 9719

<biotech gets flat and kind of bearish and our thread has dried up.> I don't know, it looks like there are several bio markets... or at least the stocks are acting independantly... some are washing out terribly, but many are rebounding sharply off lows (CEPH, NBIX, CLTR, ALKS, come to mind). DAK

To: Rocketman who wrote (6553)	3/19/1999 1:47:00 PM
From: Volsi Mimir	Read Replies (1) \| Respond to of 9719

and our thread has dried up Hey RMan maybe you can tell a joke! :) eddy (E7) how about this since its so quiet and not on your portfolio: VION Thursday March 18, 11:47 am Eastern Time Company Press Release SOURCE: Vion Pharmaceuticals, Inc. Vion Files U.S. IND to Begin Human Safety Studies with TAPET; Company Also Preparing for European Trials of this Novel Anticancer Approach NEW HAVEN, Conn., March 18 /PRNewswire/ -- Vion Pharmaceuticals (Nasdaq: VION - news) today announced that the company has filed an Investigational New Drug (IND) application with the Food and Drug Administration to begin a Phase I safety trial in the United States of its lead TAPET(TM) vector, VNP20009. The single-site trial will investigate the human clinical safety of intratumoral injections of the ''unarmed'' TAPET vectors in patients with solid tumors. ''The U.S. filing is a major addition to the existing regulatory filings that Vion has made in support of clinical trials of TAPET in Europe,'' said Alan Kessman, chief executive officer of Vion. ''This event is an important milestone for Vion, and reflects an extraordinary commitment by Vion and our collaborators at Yale University.'' TAPET vectors are Salmonella bacteria that Vion has genetically engineered for safety and the ability to preferentially target solid tumors over normal tissues for the treatment of cancer. Preclinical studies with TAPET have shown the vectors' safety and ability to suppress tumor growth in a variety of animal models. Vion plans to develop the TAPET vectors as a platform for the systemic delivery of a variety of anticancer agents directly to solid tumors throughout the body. Vion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel products and technologies for the treatment of cancer and viral diseases. The company has extensive research and development pipeline focused on five principal projects: Promycin® (porfiromycin), a hypoxic cancer cell therapy currently undergoing Phase III clinical testing; TAPET®, the company's platform cancer treatment technology; Triapine(TM), a ribonucleotide reductase inhibitor currently in a Phase I clinical trial; Beta-L-FD4C, a novel nucleoside analog for the treatment of vital diseases; and sulfonyl hydrazine prodrugs, for the treatment of cancer. For additional information on Vion and its research and product development programs, visit the company's Internet web site at vionpharm.com. Statements included in this press release which are not historical in nature are forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward- looking statements regarding the Company's future business prospects, plans, objectives, expectations and intentions are subject to certain risks, uncertainties and other factors that could cause actual results to differ materially from those projected or suggested in the forward-looking statements, including, but not limited to those contained in the Company's Registration Statement filed on Form S-3 (file no. 333-61477). CONTACT: Investors - Thomas E. Klein of Vion Pharmaceuticals, 203-498-4210; or Media - Joan Kureczka, or Jesse Fisher of J. Kureczka Associates, 415-821-2413, for Vion Pharmaceuticals. SOURCE: Vion Pharmaceuticals, Inc. -------------------------------